Sanne van Wissen

Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial

TJ Smilde, Sanne van Wissen, H Awollersheim et al. · The Lancet · 2001 · 920 citations

Metabolic Syndrome, Lipid Disorder, Atherosclerosis Progression +9

Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors

Truman J. Milling, Saskia Middeldorp, Lizhen Xu et al. · Circulation · 2023 · 132 citations · Full text

Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy

Sanne van Wissen, Mieke D. Trip, Tineke J. Smilde et al. · Atherosclerosis · 2002 · 115 citations

Familial Hypercholesterolemia, Lipid Disorder, Cardiovascular Disease +8

Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy

Anne Grete Semb, Sanne van Wissen, Thor Ueland et al. · Journal of the American College of Cardiology · 2003 · 112 citations

Soluble Cd40 Ligand, Metabolic Syndrome, Lipid Disorder +10

Individualised versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome (IDEAL DVT): a multicentre, randomised, single-blind, allocation-concealed, non-inferiority trial

Arina J. ten Cate‐Hoek, Elham E Amin, A.C. Bouman et al. · The Lancet Haematology · 2017 · 95 citations · Full text

Thrombosis, Venous Disease, Venous Thrombosis +13